Park Jung Won
- 専門分野: Gastroenterologist
- 41年の経験
- 話します:Korean
- 勤務先: 大韓民国, 高陽, Myongji Hospital
- Led Korea’s first multidisciplinary HCC clinical practice guidelines in 2003 and oversaw subsequent revisions.
Professor Park Jung-won is a leading Korean specialist in hepatocellular carcinoma with over 30 years of experience. He is the Director of the Liver and Liver Cancer Center and the Integrated Cancer Care Center at Myongji Hospital. He led Korea’s first HCC guidelines in 2003. He has also overseen their updates for about 20 years. His team validated proton beam radiotherapy for liver cancer, as published in the Journal of Hepatology. He has authored more than 200 SCI-indexed papers. He also helped lead global trials, including the 2025 CheckMate 9DW study, which showed improved outcomes with nivolumab plus ipilimumab for unresectable HCC.
MD/PhD, Seoul National University; Member, National Academy of Medicine of Korea; former President, Korean Liver Cancer Association; Chair, Korean HCC Guidelines Committee; Prime Minister’s and Health Minister’s commendations; Pfizer Medical Research Award and Roche Oncology Academic Award.
医師のサービス
調子はいかがですか？
資格
Professor Park Jung-won is one of Korea’s leading liver cancer specialists and a nationally recognized authority in hepatocellular carcinoma (HCC). With more than 30 years of experience in liver disease, he specializes in the diagnosis and medical treatment of liver cancer, liver cirrhosis, hepatitis, and other chronic liver diseases. He currently serves as Director of the Liver & Liver Cancer Center and Director of the Integrated Cancer Care Center at Myongji Hospital.
Professor Park has played a major role in shaping liver cancer treatment standards in South Korea. In 2003, he led the development of Korea’s first multidisciplinary clinical practice guidelines for hepatocellular carcinoma and continued to lead their revisions for approximately 20 years. His research also demonstrated the effectiveness and safety of proton beam radiotherapy for liver cancer, with the results published in the Journal of Hepatology. He has led and participated in numerous international clinical trials of new treatments for liver cancer and has published more than 200 SCI-indexed papers on liver cancer, hepatitis B, cirrhosis, and related liver diseases. In 2025, he also reported results from the multinational Phase III CheckMate 9DW trial showing improved outcomes with nivolumab plus ipilimumab for unresectable hepatocellular carcinoma.
Education
- MD, Seoul National University College of Medicine
- PhD in Medicine, Seoul National University Graduate School of Medicine
Professional Experience
- Director, Liver & Liver Cancer Center, Myongji Hospital — Current
- Director, Integrated Cancer Care Center, Myongji Hospital — Current
- Clinical Professor of Gastroenterology, Myongji Hospital
- Former Senior Researcher, National Cancer Center Korea
- Former Director, Liver Cancer Center, National Cancer Center Korea
- Former Director, National Cancer Center’s Anticancer Drug & New Treatment Development Program
- Former Adjunct Professor, National Cancer Center Graduate School of Cancer Science and Policy
- Research Fellow, Mayo Clinic Digestive Diseases Research Center, USA
- Former Associate Professor of Gastroenterology, Chung-Ang University College of Medicine
Professional Activities
- Former President, Korean Liver Cancer Association
- Full Member, National Academy of Medicine of Korea
- Chairman, Korean HCC Clinical Practice Guidelines Committee
- Former Scientific Committee Chairman, Asia-Pacific Primary Liver Cancer Expert Association (APPLE)
- Former Executive Board Member, International Liver Cancer Association (ILCA)
- Former Scientific Committee Chairman, Korean Association for the Study of the Liver
Awards
- Prime Minister’s Commendation for Advancement of Health and Medical Technology
- Pfizer Medical Research Award, National Academy of Medicine of Korea
- Minister of Health and Welfare Commendation for Clinical Research
- Minister of Health and Welfare Commendation for Contributions to Cancer Care
- Hamchoon Medical Award, Seoul National University College of Medicine
- Roche Oncology Academic Award
- Best Paper Awards from the Korean Association of Internal Medicine and the Korean Association for the Study of the Liver
Research
- More than 200 SCI-indexed publications in liver cancer, hepatitis B, liver cirrhosis, and other liver diseases
- Principal involvement in multiple national and multinational clinical trials for new liver cancer therapies
こちらもご興味をお持ちいただけるかもしれません
支払い・特典
当社サービスへのお支払いはありません
クリニックで直接またはその公式銀行口座にお支払いいただきます。
一部のクリニックでは保証金が必要な場合があります。
分割払いオプションでお支払いを分散してください。
Bookimedにお友達を紹介して報酬を獲得してください。